AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement with Cogia Biotech LTD

AIkido Pharma | May 06, 2020

AIkido Pharma Inc. (Nasdaq: AIKI) today announced execution of an Artificial Intelligence (AI), and Machine Learning (ML) research agreement with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the Company's pancreatic cancer genetic marker research.  Cogia is a Big-data, AI, and ML software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development.  Cogia provides state-of-the-art digital information and discovery tools to subject-matter experts and scientists working in genetics and cancer research, to advance drug development.  Cogia's existing clients include many international companies, including international pharmaceutical companies. Cogia will augment the Company's efforts of using machine learning to find genetic markers that could lead to pancreatic cancer. As with many cancers, early detection is vital, but in pancreatic cancer, surgical intervention is currently the only effective treatment for the extension of life. Pancreatic cancer is relatively rare; however, it is the third leading cause of cancer deaths in the United States.  The disease is often asymptomatic, making early detection and treatment difficult or even impossible. Only 20% of individuals are diagnosed with pancreatic cancer early enough to be surgical candidates. Reliable markers for early detection will expand the number of patients who are eligible for life-extending surgery. Andreas Typaldos, Executive Chairman of Cogia Biotech, expressed his excitement about the research agreement with AIkido. "Even during the preparatory work leading up to this strategic agreement with AIkido, one could see the promise of compelling outcomes in early and better detection of pancreatic cancer and possibility for novel and more effective therapeutics using state-of-the-art technologies like AI and ML. The very earliest project-design work sessions between Cogia Biotech AI/ML data scientists, bio-informatics engineers, and cancer research scientists, on one hand, and AIkido and University of Texas Southwestern Medical Center research scientists, on the other, clearly pointed to how compelling and appropriate is the vision of Anthony Hayes for having AIkido use of these breakthrough biotech technologies in disease detection and drug development. We are excited and honored to be part of Anthony's plan and effort.

Spotlight

Go inside a clinical microbiology lab at Penn State Milton S. Hershey Medical Center and learn about careers in clinical microbiology.

Spotlight

Go inside a clinical microbiology lab at Penn State Milton S. Hershey Medical Center and learn about careers in clinical microbiology.

Related News

MEDICAL

Bio Detection K9 Develops Cutting-Edge Detection for Grape Virus Diseases

Bio Detection K9 | May 19, 2022

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseases, BDK9 is launching a cost-effective service that can quickly and accurately pinpoint infected vines before the pathogens have a chance to spread. Utilizing proprietary technology, BDK9 develops training aids that have the scent of the target viruses. The result is a harmless substance with a highly specific scent that dogs are systematically trained to detect. This is the same proven methodology BDK9 employs to screen humans for COVID-19 at airports, stadiums and public events worldwide. The challenge is like finding a needle in a haystack when trying to detect an infected plant among thousands of potentially threatened vines, But thanks to our completely safe training aid, we can teach canines to accurately detect a viral disease in any tissue, roots, vines, or leaves." Dr. William Schneider, Chief Research Scientist for BDK9. BDK9's unique technology is effective in many different areas, from humans to agriculture, and the company is proud to be at the forefront of disease detection. We're thrilled about the release of this new, cutting-edge technology and are pleased to offer this to the wine industry, Our company continues to set the standard in agriculture disease detection with our effective programs, and we take great pride in the fact that we're able to take action and truly address these important issues as they arise. " Wade Morrell, CEO of BDK9. About Bio Detection K9 Bio Detection K9 (BDK9) is the world leader in precision agriculture and human host pathogen bio detection. Led by a veteran USDA virologist, BDK9 works with canines and cutting-edge technology to identify disease in both humans and agriculture. Their dogs are trained to isolate individual pathogens with unparalleled accuracy and specificity. All training is performed safely and Bio Detection Canines™ are unharmed during the process. BDK9 is not only at the forefront of precision pathogen detection through this unique combination of technology and training, but their services are efficient, cost effective and non-invasive.

Read More

MEDICAL

CosmosID® Enters Microbiome Partnership with Locus Biosciences

CosmosID | June 22, 2022

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. Locus is developing two innovative biotherapeutics categories to meet significant unaddressed medical needs. First, engineered bacteriophage therapies that use bacteria resident in specific body locations to dispatch therapeutic molecules. Second, precision CRISPR-enhanced bacteriophage (crPhage®) products to combat fatal infections, including the ones caused by multi-drug resistant bacteria. Locus is able to swiftly recognize, distinguish, engineer, and produce bacteriophage products against bacterial targets involved in the pathogenesis of numerous diseases by collaborating discovery automation, industry-leading informatics, synthetic biology, and sophisticated in-house manufacturing. CosmosID's infrastructure for providing access to compliant, higher resolution, and robust microbiome analysis will allow Locus to enhance its capability and add insight into precision therapeutics platforms. With its shotgun metagenomics, the company will assist Locus in understanding its products' effectiveness through CosmosID's robust resolution microbiome analysis, commencing with its urinary tract infection clinical program. We're thrilled to partner with Locus on its groundbreaking clinical pipeline as we help the company better understand the impact of these phages on the microbiome, Locus' robust and diligent approach to this study is much needed in the field and we look forward to helping them build a strong clinical data package." Manoj Dadlani, CEO of CosmosID. This partnership with CosmosID will allow Locus to monitor microbiome changes upon treatment of patients with antibiotics and with crPhage, helping us to evaluate the impact of preserving and protecting their microflora while clearing their infections." Paul Garofolo, CEO of Locus Biosciences.

Read More

INDUSTRIAL IMPACT

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

Enveric Biosciences, Inc | July 14, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property advances achieved during the first half of 2022. “The first half of 2022 was foundationally successful for Enveric. We validated and executed on the corporate premise that we can deploy PsyAITM, our proprietary artificial intelligence tool, and PsybraryTM, our expanding proprietary portfolio of new chemical entities and drug candidates, to design and improve upon new drug molecules inspired by legacy psychedelic drugs,” Dr. Joseph Tucker, PhD, Enveric’s Chief Executive Officer “Enveric is pleased to advise that our predictions have materialized, and our platforms have successfully generated a large number of promising new molecules that have successfully passed primary screening and moved on to lead optimization, providing us with a strong slate of drug candidates. Our leading program, EVM-201, includes a number of new molecules currently in lead optimization that are geared towards providing improved characteristics and drug-like properties compared with psilocybin. The successful outcomes from our testing efforts completed in the first half of 2022 have positioned the company very well to advance our drug candidates towards the clinic,” continued Dr. Tucker. Clinical-Need Driven Based on extensive direct clinical understanding of the current unmet needs in anxiety, depression, PTSD, and other mental health indications, coupled with in-depth knowledge of the current treatment landscape, Enveric’s Clinical Team is well positioned to tackle the challenges ahead, while aiming to shepherd novel new treatments for a host of mental health indications. Enveric’s Clinical Team is led by a past Board-certified psychiatrist and clinical trialist Chief Medical Officer, Dr. Bob Dagher, MD. Dr. Dagher joined Enveric in December 2021, bringing a wealth of clinical trial management and new CNS-drug development experience from his past roles, including at WCG, Cadent, Covance, Sanofi and GSK, in addition to his first-hand experience in treating patients from his previous clinical practice in psychiatric medicine. Next-Generation Drug Discovery Enveric’s Discovery Team, spearheaded by Chief Innovation Officer Dr. Peter Facchini, PhD, an international leader in natural product biochemistry and biotechnology, completed the rational design of more than 300 Generation-2 (“Gen-2”) psilocin prodrug candidates using well-established design strategies, but adapted to the unique structure of psilocin. The 300 Gen-2 original concept designs, now housed within the PsybraryTM, were screened using PsyAITM. The assessment helped predict chemical structures with appropriate receptor binding, toxicology, and pharmacokinetic profiles that would trigger the desired mechanisms of action while reducing undesirable side effects, and the initial candidate evaluation included, among other metrics, prodrug-likeness, toxicity, ease of chemical synthesis and degree of IP-white space surrounding the molecule. Ranked scoring of these and other AI assessments, as well as commercial considerations (e.g., ease of procuring synthetic starting materials), prioritized 31 novel Gen-2 molecules that have been synthesized in sufficient quantities (~10 mg, 95% purity) for preliminary pharmacological screening. Enveric’s Chemistry Group, led by Dr. Kaveh Matinkhoo, PhD, completed these syntheses, 29 of which were deemed stable enough to advance. Deep-dive chemical structure searches, patentability, and freedom-to-operate reviews were performed on all 29 candidates, under the leadership of Lead Internal Counsel C. Michael Gegenheimer. All the patentability analyses indicated potential patentability results, and 25 of the 29 molecules presented minimal concern with freedom to operate. To strengthen the IP protection for the overall Gen-2 prodrug program, three provisional patent applications, covering 7 structurally diverse clinical classes and thousands of additional potential new drug candidates, have been filed so far in 2022, and additional provisional and PCT filings are expected to continue throughout the year. In other IP developments, an additional three of Enveric’s international patent applications protecting tryptamine derivatives have been published by the World Intellectual Property Organization, bringing the total published so far to seven. EVM-201 Drug Candidate Testing Following the initial Gen-2 ideation, patent filing, synthesis, and screening efforts, more extensive assays were performed on the advancing drug candidates. Numerous internal assays were performed under the leadership of Dr. Jill Hagel, PhD, Vice-President of Innovation and Dr. Sheetal Raithatha, PhD, Director of Research and Development. The internal results were then confirmed and validated using leading independent, third-party Contract Research Organizations (CROs), covering 122 Toxicology tests, 72 receptor-binding and potency tests, 31 pharmacokinetic tests and 24 animal-model tests to provide ample information to support candidate nomination. The synthesis and analysis of these comprehensive pharmacology and toxicology datasets, both internal and external, was led by Dr. Kevin Leach, PhD DABT, Vice President of Preclinical and Translational Research. Enveric is now moving towards lead-candidate nomination and, in preparation for IND filing, has initiated numerous IND-enabling studies on several of the leading candidates at third-party CROs. Recognizing the need for stable drugs with robust, reproducible, and cost-effective manufacturing, several Contract Development & Manufacturing Organizations (CDMOs) are currently engaged with Enveric’s Chemistry Team to determine how best to manufacture our molecules. Enveric has plans in place to produce material at commercial facilities and the CDMO personnel have worked with our chemists to validate that our processes will work at their facilities. This is another necessary step prior to filing the IND. Finally, preliminary formulation work is underway, with a particular focus on enabling improved routes of administration. “The first half of the year has indeed been busy and productive for the dedicated team here at Enveric. We are all very excited at how those efforts have begun to bear fruit. We look forward to advising our shareholders of further key developments, which we anticipate will continue to unfold during the remainder of 2022,” concluded Dr. Tucker. About Enveric Biosciences Enveric Biosciences, Inc. is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric's robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more.

Read More